CD70 and non-small cell lung carcinoma: Previous studies of our group have demonstrated overexpression of the tumor antigen, CD70, on malignant cells in 16% of NSCLC patients and its absence on normal lung tissue, making it an attractive target for antibody-based therapies [3].